Alkermes Launches 7th Annual Pathways Research Grants Program
Alkermes Introduces 7th Annual Pathways Research Awards Program
Alkermes plc (Nasdaq: ALKS) is thrilled to announce the launch of its seventh annual Alkermes Pathways Research Awards program. This initiative aims to support emerging researchers dedicated to advancing our understanding of psychiatric diseases, particularly schizophrenia and bipolar disorder. The application process will commence shortly.
About the Pathways Research Awards Program
The Alkermes Pathways Research Awards are structured as a competitive grant program, providing individual grants of up to $100,000 per project. This year, the application window will be open from late September through the end of November, allowing ample time for interested researchers to submit their proposals.
Eligibility Criteria for Applicants
To be considered for these prestigious grants, applicants must be early-career investigators, including M.D.s, Ph.D.s, or those with equivalent qualifications. They should be within five years of their initial academic appointment or currently in post-doctoral fellowships. While the program primarily supports researchers affiliated with medical or research institutions, it seeks to empower those who exhibit a strong commitment to psychiatric research.
Impact of the Awards Program
Since its inception in 2018, the Pathways program has awarded approximately $2.5 million in total funding to 25 researchers. Recipients have successfully published their findings in respected journals and presented their work at various conferences, highlighting the program's vital role in promoting groundbreaking neuroscience research.
Statements from Alkermes Leadership
Craig Hopkinson, M.D., Chief Medical Officer and Executive Vice President of Research and Development at Alkermes, shared insights about the program's intent. "The Alkermes Pathways Research Awards program underscores our dedication to neuroscience. We are excited to see how grantees will further explore complex psychiatric conditions, contributing significantly to this critical field of study," he commented.
Previous Success Stories
Over the past six years, numerous award recipients have made significant contributions to neuroscience, engaging in impactful research that often paves the way for future studies. Some grantees have even harnessed their Pathways-funded initiatives to secure funding from other reputable organizations.
How to Apply for the Awards
Researchers interested in applying for the 2024 Alkermes Pathways Research Awards are encouraged to visit the dedicated application page. Detailed information on eligibility, application procedures, and deadlines will be provided there.
Alkermes Commitment to Neuroscience
Alkermes is dedicated to developing innovative therapies in the neuroscience sector. The company prides itself on its portfolio of commercial products addressing critical issues such as alcohol and opioid dependence, as well as psychiatric disorders including schizophrenia and bipolar I disorder. With a pipeline of early and late-stage candidates in development, Alkermes continues to push the envelope of scientific research in pursuit of better health outcomes.
About Alkermes plc
Alkermes plc is a global biopharmaceutical enterprise headquartered in Ireland. It operates with an aim to innovate within the field of neuroscience. The company also maintains operational sites in Massachusetts and Ohio, contributing to its research and manufacturing capabilities.
Frequently Asked Questions
What is the Alkermes Pathways Research Awards program?
The program provides grants to early-career researchers focusing on schizophrenia and bipolar disorder, promoting advancements in neuroscience.
How much funding is available through the program?
Each grant can be up to $100,000, supporting various research projects within the neuroscience field.
Who can apply for the research awards?
Eligible applicants include M.D.s, Ph.D.s, and post-doctoral fellows affiliated with medical or research institutions, ideally within five years of their first academic role.
What has been the impact of the awards to date?
Since its establishment, the program has awarded about $2.5 million, facilitating research that frequently results in publications and advancements in mental health understanding.
How can interested researchers apply?
Researchers should visit the official Alkermes Pathways Research Awards website for complete information on application procedures and eligibility requirements.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.
Related Articles
- RenovaroCube Showcases Innovative Cancer Diagnostics Research
- Wolters Kluwer Launches Podcast Series for Business Compliance
- Beny Celebrates EUPD Research Top Brand Award for 2024
- Beny's Triumph with EUPD Research Top Brand PV 2024 Award
- Innovative Hypnosis Program Offers Support for Cancer Patients
- Empowering Educational Research: AIR at SREE 2024 Conference
- Allarity Therapeutics Appoints New CFO and Grants Stocks
- Elicio Therapeutics Showcases Groundbreaking Cancer Research Efforts
- Jyske Realkredit Launches New Covered Bonds in Copenhagen
- Similarweb Ltd. Launches Major Share Offering to Boost Growth
Recent Articles
- 65 Equity Partners Strengthens Portfolio with Kendra Scott Investment
- U.S. Consumer Loan Delinquencies Show Signs of Stabilization
- Disney Rises to Emmy Glory Under Dana Walden's Leadership
- Goldman Sachs Urges Investors to Buy AI Stocks During Dip
- Carnival's Remarkable Comeback: What to Expect Next Year
- Intel's Roadmap: Challenges and Strategic Options Ahead
- Emergent BioSolutions Reaches Settlement in Class Action Case
- ANI Pharmaceuticals Introduces New Cough Relief Solution
- UnitedHealth Group's Upcoming Earnings Release and Insights
- Occidental's 1PointFive Secures Major Funding for CO2 Capture
- BMC Medical Co., Ltd. Celebrates New France Office Opening
- Highlighted Tech Developments You Might Have Missed This Week
- Kenny Dichter Introduces REAL SLX for Unmatched Experiences
- Business Jet Market Expected to Reach $156 Billion by 2032
- European Nations Unite Against IMF's Russia Mission Plans
- Insight Partners Eyes Over $4 Billion Sale of Tricentis Software
- JPMorgan Insights: Soft Landing Predicted Amidst Political Trends
- Danone Faces Downgrade Amid Concerns Over Growth Segments
- Market Update: India's Stocks Experience Minor Declines
- BYD Expands Workforce Amid Job Creation Push by Government
- Market Dynamics: Futures Flat Amid Fed Rate Speculations
- Exploring Future Growth of the Nanocellulose Market
- Pet Supplements Market Expected to Reach $5.54 Billion by 2033
- Market Overview: Oil Up, Gold Soars, Dollar Weakens Amid Shifts
- Market Sentiment Shifts with Fed Meeting Approaching: Key Insights
- Medius Awarded Prestigious 2024 ISV Partner of the Year
- Catalyst Metals Plans Major Gold Production Increase Ahead
- Automotive Gears Market Forecast: A Look Toward 2030 Growth
- Medius Honored as Top Microsoft Partner for Innovative Finance
- Latest Highlights in Retail: Exciting Updates You Shouldn't Miss
- Amazon: The Untapped Potential of AI and Retail Growth
- Buffett's Strategy: Selling Bank of America, Buying Berkshire Shares
- Greene's Growing Stock Ventures: Insights into AI Investments
- Trifork Group AG's Recent Transactions by Management Personnel
- Daily Fund Prices and Insights from WisdomTree Issuer
- Scottie Pippen's Exciting Bitcoin Predictions Spark Interest
- Wall Street Experts Revise Ferguson Enterprises Q4 Earnings Outlook
- Exploring Recent Insider Sales: Key Trades by Notable Companies
- Exciting Opportunities in Materials Stocks for Investors
- Key Finance Updates: Noteworthy Business Developments This Week
- Antiscalants Market Set to Reach $5.9 Billion by 2029
- Empowering Future Leaders at Grant Thornton Greece with Innovative Training
- AI Summit 2024 Closes With Major Partnerships and Innovations
- Essential Healthcare Updates: Key Press Releases You Need to Know
- Gold Shines Bright Amid Shifting Federal Reserve Policies
- TikTok's Legal Battle: A Turning Point for Social Media in the US
- Warren Buffett's Latest Moves: Selling Stocks and Buying Strong
- Why Procter & Gamble, Hormel, and Hershey Are Essential Stocks
- Exploring the Expansive Future of the Anime Market
- NioBay Metals Advances with Authorization for Surface Drilling